Compare Organon & Co. Common Stock (OGN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs ABRDN Physical Gold Shares ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while ABRDN Physical Gold Shares ETF trades at $39.52 (market cap $7.18B). The key difference: ABRDN Physical Gold Shares ETF is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| OGN | SGOL | |
|---|---|---|
Market Cap | $3.62B | $7.18B |
Volume | 2,892,999 | 2,482,796 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $13.81 | $51.41 |
52-Week Low | $5.70 | $37.54 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SGOL trades at $39.63, down 0.13% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX showing sell signals. Support levels cluster around $39-40, while resistance is firm at $40. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices pressured by rising rates but supported by geopolitical tensions and strong Chinese imports.
The outlook remains cautious amid interest rate uncertainty, with potential for rebound if yields stabilize or conflict escalates. Risks include persistent inflation driving higher rates, while institutional analysts see mixed paths—some targeting $4,100 by year-end but others $5,000 by mid-2027. Investor sentiment is neutral to bearish short-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
